Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
08 janv. 2024 08h00 HE
|
Wave Life Sciences USA, Inc.
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans Selection of...
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
15 déc. 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data demonstrated highest level of exon skipping ever...
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
07 déc. 2023 07h00 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
06 déc. 2023 16h10 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
06 déc. 2023 16h08 HE
|
Wave Life Sciences USA, Inc.
Wave Life Sciences Announces Initiation of Dosing in Clinical Trial Evaluating First-Ever RNA Editing Candidate, WVE-006, in Alpha-1 Antitrypsin Deficiency
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
22 nov. 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
09 nov. 2023 07h30 HE
|
Wave Life Sciences USA, Inc.
Initiated RestorAATion clinical program for WVE-006, industry’s first-ever RNA editing clinical candidate, following approval of CTAs; dosing on track for 4Q 2023 and first-in-human proof-of-mechanism...
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
03 nov. 2023 16h05 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
28 sept. 2023 16h15 HE
|
Wave Life Sciences USA, Inc.
Presented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Wave’s best-in-class GalNAc-siRNA capabilities and...